Vijayshree Yadav, M.D.
- click here
- 503 494-7772
Dr. Yadav is a board certified neurologist who received her medical degree in 1995 from SN Medical College in Agra, India. She completed her fellowship in Neuroimmunology and Multiple Sclerosis at Oregon Health & Science University and Portland VA Medical Center in 2004. In 2004, she joined the OHSU MS Center and is an Assistant Professor in the Department of Neurology. She received her Masters in Clinical Research in 2008 and in 2010 was appointed Clinical Medical Director of the OHSU MS Center.
Dr. Yadav's research interests include complementary and alternative treatment options for multiple sclerosis including dietary and life style changes as well as supplements such as lipoic acid. She has published several peer reviewed journal articles and presented her research at national and international meetings.
Summary of Current Research
Lipoic acid attenuates inflammation via cAMP and protein kinase A signaling, Sonemany Salinthone, Robynn V. Schillace, Vijayshree Yadav, Dennis N. Bourdette, Daniel W. Carr submitted June 2010 The Journal of Immunology.
Oral disease modifying therapies for MS: Are we there yet? Yadav V, Bourdette D. Curr Neurol Neurosci Rep. Submitted April 2010 ( In press)
Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Lovera J, Frohman E, Brown T, Bandari D, Nguyen L, Yadav V, Stuve O, Karman J, Bogardus K, Heimburger G, Cua L, Remingon G, Fowler J, Monahan T, Kilcup S, Courtney Y, McAleenan J, Butler K, Wild K, Whitham R, Bourdette D. Mult Scler. 2010 May 18.
Complementary and alternative medicine for the treatment of multiple sclerosis. Yadav V, Shinto L, Bourdette D. Expert Rev Clin Immunol. 2010 May; 6(3):381-95.
Clinical trial of formal group fatigue program in multiple sclerosis C Hugos, L. Copperman, Fuller, V Yadav, J Lovera, DN. Bourdette, Mult Scler Apr 7 2010
Pharmacokinetic study of lipoic acid in multiple sclerosis: Comparing mice and human pharmacokinetic parameters. Yadav V, Gail H Marracci, Myrna Y. Munar, Ganesh Cherala, Lauren E Stuber, Lilia Alvarez, Lynne Shinto1, Dennis R. Koop, Dennis N. Bourdette. Mult Scler. 2010 Apr; 16(4):387-97.
Alemtuzumab versus interferon Beta-1a in early multiple sclerosis. Bourdette D, Yadav V. Curr Neurol Neurosci Rep. 2009 Sep; 9(5):341-2. Apical ballooning resulting from limbic encephalitis. Gelow J, Kruer M, Yadav V, Kaul S., Am J Med. 2009 Jun;122(6):583-6.
Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis. Shinto L, Marracci G, Baldauf- Wagner S, Strehlow A, Yadav V, Stuber L, Bourdette D. Prostaglandins Leukot Essent Fatty Acids. 2009 Feb-Mar; 80(2-3):131-6.
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. Bourdette D, Yadav V. Curr Neurol Neurosci Rep. 2008 Sep; 8(5):417-8.
Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflammatory diseases of the CNS. Salinthone S, Yadav V, Bourdette DN, Carr DW. Endocr Metab Immune Disord Drug Targets. 2008 Jun; 8(2):132-42.
A randomized pilot study of naturopathic medicine in multiple sclerosis. Shinto L, Calabrese C, Morris C, Yadav V, Griffith D, Frank R, Oken BS, Baldauf- anger S, Bourdette D. J Altern Complement Med. 2008, Jun;14(5):489-96.
Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis.
Vandenbark AA, Culbertson NE, Bartholomew RM, Huan J, Agotsch M, LaTocha D, Yadav V, Mass M, Whitham R, Lovera J, Milano J, Theofan G, Chou YK, Offner H, Bourdette DN. Immunology. 2008 Jan; 123(1):66-78.
Complementary and alternative medicine: is there a role in multiple sclerosis? Yadav V, Bourdette DN: Curr Neurol Neurosci Rep. 2006 May; 6(3): 259-67
Use and self reported benefit of complementary and alternative (CAM) therapies among multiple sclerosis patients. Yadav V, Shinto L, Morris C, Senders A, Baldauf-Wagner S, Bourdette DN: International Journal of MS Care 2006, 8(1): 5-10
Demographic and health-related factors associated with complementary and alternative medicine (CAM) use in multiple sclerosis. Shinto L, Yadav V, Senders A, Morris C, Lapidus J, Bourdette B: Mult Scler. 2006 Feb; 12(1): 94-100.
The perceived benefit and satisfaction from conventional and complementary and alternative medicine (CAM) in people with multiple sclerosis. Shinto L, Yadav V, Senders A, Morris C, Bourdette B: Complement Ther Med. 2005 Dec; 13(4): 264-72
A highly immunogenic trivalent T cell receptor peptide vaccine. Bourdette DN, Edmonds E, Smith C, Bowen JD, Guttmann CR, Nagy ZP, Simon J, Whitham R, Lovera J, Yadav V, Mass M, Spencer L, Culbertson N, Bartholomew RM, Theofan G, Milano J, Offner H, Vandenbark AA. Mult Scler 2005 11(5): 552-61.
Lipoic acid in multiple sclerosis: a pilot study. Yadav V, Marracci G, Lovera J, Woodward W, Bogardus K, Marquardt W, et al. Mult Scler 2005; 11(2): 159-165.
"Complementary and alternative medical therapies in multiple sclerosis - The American Academy of Neurology Guidelines: A commentary,"
"Perceived Stress in Multiple Sclerosis: The Potential Role of Mindfulness in Health and Well-Being,"
"Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology,"
"New disease-modifying therapies and new challenges for MS,"
"Recombinant T-cell receptor ligand (RTL) for treatment of multiple sclerosis: A double-blind, placebo-controlled, phase 1, dose-escalation study,"